Pepscan Therapeutics has earned a milestone payment from Genmab from an ongoing research collaboration aimed at identifying human antibodies against intractable targets. Pepscan is responsible for using its CLIPS technology to generate immunogens that mimic the protein targets to induce human antibodies against these intractable targets. Pepscan is eligible to receive additional payments based on certain development and regulatory milestones and is eligible to receive royalties on potential s...